99% of process manufacturers preparing for growth despite market challenges

The Manufacturer | May 17, 2019

Growing regulatory change and uncertainty is impacting the vast majority of UK process manufacturers, but they are responding by investing in new technologies and leveraging the cache surrounding Brand Britain. As political uncertainty bites, almost two-thirds of process manufacturers (62%) say regulatory changes are affecting their business, with more than four-in-five (82%) revealing the threat of import-export shake-ups around Brexit having significant impact on strategic decision-making.
Despite those challenges, however, that same number (82%) are confident their UK home-grown industry will be considered a world leader by 2025, and an overwhelming 99% of all process manufacturers say they are preparing for growth, suggesting a can-do attitude on both sides of the Atlantic. The figures come from the latest global state of the nation report on process manufacturing from cloud business management solutions provider Sage. The research covers businesses in the UK, US and Canada, and reveals a sector that’s taking charge of its own destiny despite growing change and uncertainty.

Spotlight

Electronic Manufacturing Service (EMS) providers offer viable solutions to cost, performance and quality issues for virtually any size ODM (original design manufacturer) or Tier 1 supplier. Many of the outsourcing arguments that hold true for other industries hold true for EMS — focusing on core competency, preserving capital and leveraging expertise — but Electronic Manufacturing Outsourcing (EMO) offers significant value in flexibility and product lifecycle.

Spotlight

Electronic Manufacturing Service (EMS) providers offer viable solutions to cost, performance and quality issues for virtually any size ODM (original design manufacturer) or Tier 1 supplier. Many of the outsourcing arguments that hold true for other industries hold true for EMS — focusing on core competency, preserving capital and leveraging expertise — but Electronic Manufacturing Outsourcing (EMO) offers significant value in flexibility and product lifecycle.

Related News

MANUFACTURING TECHNOLOGY

Tritium and Aqua superPower Form Strategic Partnership to Power Electric Boats

Aqua superPower | December 23, 2021

On December 22, Aqua superPower, the world's first marine fast-charging network operator, and Tritium Holdings Pty Ltd, a global leader in developing and manufacturing direct-current fast charging technology for electric vehicles, announced a strategic partnership to electrify transportation on international waterways. Aqua superpower has been expanding its network of fast maritime chargers, with recent installations in the Cote d'Azur and the Italian Riviera, another in Venice, and another 150 chargers scheduled for next year, followed by further deployment expansion. While the electric transportation revolution keeps sweeping the roads and skies, the aquatic environment is also electrifying. Aqua superpower works with marinas, boat builders, and boat owners to lessen the effect of boating on marine ecosystems. In addition, Aqua is working with Tritium, a global leader in DC fast charging hardware and software, to build the first global marine-specific fast-charging network. We elected to work with Tritium for their forward-thinking technology, cutting-edge hardware architecture, and operational cost benefits,” said “The requirement for a joined-up network of reliable and fast marine chargers to create charging hubs and corridors for electric boat users is absolutely crucial if we are to secure the transition away from liquid carbon fuels. The fully sealed design of Tritium’s DC fast chargers and the clarity of the user interface inherently provide the robustness and ease of use needed in the marine and freshwater environments.” Aqua superPower’s CEO, Alex Bamberg For the e-boat business to expand, DC fast charger charging speed is crucial. Worldwide, business and recreational marine craft users rely on Aqua for dependable, high-speed charging. A fully sealed, safe, and dependable charging station for e-boat drivers is IP65-rated Tritium technology. With dual CCS connectors and simultaneous charging capability, the company's RTM fast charger type was suitable for Aqua. The chargers' more frequent duty cycles make e-boat technology both more efficient and better for the locations in which it is utilized. The existing high-profile installations in Monaco, Portofino, and Venice, together with other planned Aqua superPower and Tritium projects around the world, will support the electrification of marine transportation going forward. In the same way that passenger vehicles have reached their tipping point, the future for boating is an electrified fleet. The Aqua team comes with experience in creating fast charging networks. We are delighted to work with them as a marine channel partner and provide the technology to help them pursue their goal of a dedicated marine fast charge network.” Tritium’s CEO, Jane Hunter Tritium's weather-proof hardware effortlessly integrates with Aqua superPower's network and user management technologies. Maritime e-mobility requires an intuitive user interface that directs users to charging stations to be widely adopted. The Aqua secure app, RFID card, and contactless payment are now available for maritime users, with ‘Plug and Charge' technologies coming soon. The software will display users a map with charging alternatives and provide navigational aids to their chosen spot. Aqua's use of Tritium's technology will help it achieve its goal of creating an all-electric worldwide marine rapid charger ecosystem. The partnership will include ferries, shuttles, and boats used for washing and food delivery, as well as fishing and passenger transport.

Read More

MANUFACTURING TECHNOLOGY

Atara Biotherapeutics and Fujifilm Form Strategic Manufacturing Partnership

Atara | January 27, 2022

On January 26, Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, announced that it has entered into a long-term strategic agreement with FUJIFILM Diosynth Biotechnologies (FDB), a subsidiary of FUJIFILM Corporation (Fujifilm), under which Fujifilm will acquire Atara's T-Cell Operations and Manufacturing (ATOM). A long-term supply agreement, possibly lasting ten years, will also be signed by the parties. Following the completion of the transaction, FDB, a leading contract development, and manufacturing organization (CDMO) focused on advanced therapies, will provide Atara with access to the flexible capacity and specialized capability necessary to manufacture clinical-and commercial-stage allogeneic cell therapies for its maturing and promising pipeline, including tabelecleucel (tab-cel®), which is currently undergoing regulatory review in Europe for EBV+ PTLD, ATA188 for multiple sclerosis, and allogeneic CAR T. Additionally, FDB will increase its reliance on the Thousand Oaks facility and harness its experienced workforce to manufacture a broader array of cell therapies. Atara will retain its manufacturing process science expertise, personnel, and capabilities to continue developing the initial manufacturing and scale-up of allogeneic cell treatments. "FUJIFILM Diosynth Biotechnologies is a highly respected, quality-focused, industry-leading manufacturing and development organization that shares our pioneering culture and belief that allogeneic cell therapies will transform the future of medicine, We are incredibly proud of our world-class ATOM staff and facility and believe that this strategic partnership will meet our long-term manufacturing needs. Our team has developed processes for our products, scaled them up, and built inventory for clinical trials and the potential commercial launch of tab-cel. We believe that now is the right time for a strategic relationship with FDB to provide us with expert manufacturing capabilities, as needed. Accordingly, we will further focus our capital resources on the development and commercialization of our pipeline of potentially transformative therapeutics for serious diseases." -Pascal Touchon, President and CEO of Atara. Atara anticipates having $371.1 million in cash, cash equivalents, and short-term investments as of December 31, 2021. This information is preliminary, has not been audited, and is subject to change upon the company's financial statements for the year ending December 31, 2021, being audited. Atara will get USD 100 million upon closing, and Fujifilm intends to hire roughly 140 highly experienced manufacturing and quality personnel at the facility. In addition, the arrangement is projected to result in a multi-year reduction in Atara's planned operating expenses. Following the transaction's close, the upfront consideration, combined with the decrease in operating expenses, is expected to fund Atara's planned operations through Q4 2023, beyond the anticipated completion of the randomized, placebo-controlled Phase 2 study of ATA188, the company's investigational off-the-shelf T-cell candidate with the potential to reverse disability in progressive multiple sclerosis. Atara retains the recently established Atara Research Center (ARC) in Thousand Oaks, California. The ARC is fully operational and will house Atara's Pre-Clinical, Translational Sciences, Manufacturing Process Sciences, and Analytical Development teams, enabling the company to accelerate innovation by using the company's unique and differentiated allogeneic cell therapy platform. Additionally, Atara will retain a competent technical operations staff to manage external production, quality, logistics, and supply chain management. "We are thrilled that through this acquisition, we will add approximately 140 talented staff from Atara’s cell therapy manufacturing facility to the FUJIFILM Diosynth Biotechnologies family. The collective expertise of the team will further support our efforts as a world-class CDMO, We also look forward to adding the facility to FUJIFILM Diosynth Biotechnologies’ existing global footprint and to bolstering the expansion of our advanced therapies CDMO business." -Martin Meeson, chief executive officer, FUJIFILM Diosynth Biotechnologies ATOM is a 90,000-square-foot state-of-the-art T-cell therapy manufacturing facility that is fully qualified to support clinical and commercial production and is built to scale to meet various production requirements and capacities. The transaction is scheduled to close in April 2022, subject to the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other standard closing conditions. Atara is advised by Evercore Group LLC on a strategic level and by Gibson Dunn & Crutcher LLP on a legal one. *This press release contains or may contain "forward-looking statements," as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.

Read More

MANUFACTURING TECHNOLOGY

CMTC's Business Improvement Services Assist a Pet Product Manufacturer in Restoring Revenue to Pre-pandemic Levels

CMTC | January 24, 2022

California Manufacturing Technology Consulting® (CMTC) recently offered business improvement services to assist Jax & Bones in developing strategies for significant development and developing a future roadmap. Jax & Bones designs and manufactures luxury pet goods in the United States, utilizing sustainable materials and high-end design. The environmentally conscious company specializes in luxurious dog bedding and durable dog toys and accessories. All Jax & Bones bedding and fabric accessories are handcrafted in the company's Los Angeles manufacturing facility. Jax & Bones had grown steadily since its inception in 2004, but the COVID-19 epidemic posed substantial obstacles, resulting in income losses. As a result, the owner approached CMTC for assistance in realigning the company's goals and streamlining processes to reclaim market share and revenue levels before the pandemic. CMTC offered business improvement services that included a goal-setting session with the full Jax & Bones team, weekly leadership coaching with the company's owner, and an operational review to facilitate business expansion and collaborations. CMTC collaborated with the Jax & Bones team to develop a five-year development strategy that included staff cross-training and career path creation. Additionally, CMTC assisted management in recruiting and hiring a sales director, reworking costing sheets, and increasing the minimum salary. As a result of CMTC's ongoing support, troubleshooting, and team development, Jax & Bones anticipates a 200 percent increase in sales, $200,000 in retained sales, and $15,000 in information systems and workforce practices. Additionally, Jax & Bones anticipates creating 7-10 additional employment next year. Contact Rachel Miller at rmiller@cmtc.com or 310-984-0096 for further information about CMTC's company enhancement services.

Read More